{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T01:09:15Z","timestamp":1790816955174,"version":"4.1.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Lieselotte Beutel Foundation"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.urolonc.2019.03.001","type":"journal-article","created":{"date-parts":[[2019,4,18]],"date-time":"2019-04-18T02:06:42Z","timestamp":1555553202000},"page":"355.e1-355.e9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["sE-cadherin is upregulated in serum of patients with renal cell carcinoma and promotes tumor cell dissemination in vitro"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5107-3523","authenticated-orcid":false,"given":"Igor","family":"Tsaur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7872-5496","authenticated-orcid":false,"given":"Tanja","family":"H\u00fcsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"J\u00fcngel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederike","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meike","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Haferkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Verena","family":"Lieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Wach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helge","family":"Taubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix K.-H.","family":"Chun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman A.","family":"Blaheta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.urolonc.2019.03.001_bib0001","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.eururo.2014.10.002","article-title":"International variations and trends in renal cell carcinoma incidence and mortality","volume":"67","author":"Znaor","year":"2015","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2019.03.001_bib0002","first-page":"286","article-title":"Incidence and mortality of kidney cancer and its relationship with HDI (Human Development Index) in the world in 2012","volume":"90","author":"Mohammadian","year":"2017","journal-title":"Clujul Med"},{"key":"10.1016\/j.urolonc.2019.03.001_bib0003","article-title":"Familial renal cancer: molecular genetics and surgical management","volume":"2011","author":"Barrisford","year":"2011","journal-title":"Int J Surg Oncol"},{"issue":"3","key":"10.1016\/j.urolonc.2019.03.001_bib0004","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.eururo.2017.11.016","article-title":"Updated European Association of Urology Guidelines Recommendations for the treatment of first-line metastatic clear cell renal cancer","volume":"73","author":"Powles","year":"2017","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.urolonc.2019.03.001_bib0005","doi-asserted-by":"crossref","first-page":"804","DOI":"10.6004\/jnccn.2017.0100","article-title":"Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology","volume":"15","author":"Motzer","year":"2017","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"10.1016\/j.urolonc.2019.03.001_bib0006","doi-asserted-by":"crossref","first-page":"620","DOI":"10.21037\/tcr.2017.05.19","article-title":"Renal cell carcinoma: the search for a reliable biomarker","volume":"6","author":"Farber","year":"2017","journal-title":"Transl Cancer Res"},{"issue":"7","key":"10.1016\/j.urolonc.2019.03.001_bib0008","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/bjc.2012.360","article-title":"Prognostic utility of pre-operative circulating osteopontin, carbonic anhydrase IX and CRP in renal cell carcinoma","volume":"107","author":"Sim","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.urolonc.2019.03.001_bib0009","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1186\/1471-2407-12-399","article-title":"Validation of CRP as prognostic marker for renal cell carcinoma in a large series of patients","volume":"12","author":"Steffens","year":"2012","journal-title":"BMC Cancer"},{"issue":"6","key":"10.1016\/j.urolonc.2019.03.001_bib0010","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s00018-010-0595-0","article-title":"Modulation of E-cadherin function and dysfunction by N-glycosylation","volume":"68","author":"Pinho","year":"2011","journal-title":"Cell Mol Life Sci"},{"issue":"8","key":"10.1016\/j.urolonc.2019.03.001_bib0011","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1039\/b719215k","article-title":"Cadherins in development and cancer","volume":"4","author":"Stemmler","year":"2008","journal-title":"Mol Biosyst"},{"issue":"6","key":"10.1016\/j.urolonc.2019.03.001_bib0012","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a003129","article-title":"Involvement of members of the cadherin superfamily in cancer","volume":"1","author":"Berx","year":"2009","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.1016\/j.urolonc.2019.03.001_bib0013","series-title":"TNM classification of malignant tumors. UICC International Union Against Cancer","author":"Sobin","year":"2011"},{"key":"10.1016\/j.urolonc.2019.03.001_bib0014","series-title":"TNM supplement, a commentary on uniform use","author":"Wittekind","year":"2012"},{"issue":"7","key":"10.1016\/j.urolonc.2019.03.001_bib0015","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1097\/00000478-198210000-00007","article-title":"Prognostic significance of morphologic parameters in renal cell carcinoma","volume":"6","author":"Fuhrman","year":"1982","journal-title":"Am J Surg Pathol"},{"issue":"7","key":"10.1016\/j.urolonc.2019.03.001_bib0016","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0130975","article-title":"EphA2 is a potential player of malignant cellular behavior in non-metastatic renal cell carcinoma cells but not in metastatic renal cell carcinoma cells","volume":"10","author":"Cho","year":"2015","journal-title":"PLoS One"},{"issue":"34","key":"10.1016\/j.urolonc.2019.03.001_bib0017","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.1200\/JCO.2008.21.4809","article-title":"Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study","volume":"27","author":"Heng","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2019.03.001_bib0018","doi-asserted-by":"crossref","DOI":"10.1007\/s00345-018-2309-4","article-title":"Prognostic factors and prognostic models for renal cell carcinoma: a literature review","author":"Klatte","year":"2018","journal-title":"World J Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2019.03.001_bib0019","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0022-5347(05)66077-6","article-title":"A postoperative prognostic nomogram for renal cell carcinoma","volume":"166","author":"Kattan","year":"2001","journal-title":"J Urol"},{"issue":"23","key":"10.1016\/j.urolonc.2019.03.001_bib0020","doi-asserted-by":"crossref","first-page":"4559","DOI":"10.1200\/JCO.2002.05.111","article-title":"Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma","volume":"20","author":"Zisman","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2019.03.001_bib0021","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/408047","article-title":"Levels of soluble E-cadherin in breast, gastric, and colorectal cancers","volume":"2014","author":"Repetto","year":"2014","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.urolonc.2019.03.001_bib0022","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/B978-0-12-394311-8.00014-5","article-title":"Cadherins and epithelial-to-mesenchymal transition","volume":"116","author":"Gheldof","year":"2013","journal-title":"Prog Mol Biol Transl Sci"},{"issue":"3","key":"10.1016\/j.urolonc.2019.03.001_bib0023","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/ejhg.2012.159","article-title":"The importance of E-cadherin binding partners to evaluate the pathogenicity of E-cadherin missense mutations associated to HDGC","volume":"21","author":"Figueiredo","year":"2013","journal-title":"Eur J Hum Genet"},{"issue":"3","key":"10.1016\/j.urolonc.2019.03.001_bib0024","doi-asserted-by":"crossref","first-page":"e33783","DOI":"10.1371\/journal.pone.0033783","article-title":"E-cadherin destabilization accounts for the pathogenicity of missense mutations in hereditary diffuse gastric cancer","volume":"7","author":"Simoes-Correia","year":"2012","journal-title":"PLoS One"},{"issue":"14","key":"10.1016\/j.urolonc.2019.03.001_bib0025","first-page":"3845","article-title":"E-cadherin gene mutations provide clues to diffuse type gastric carcinomas","volume":"54","author":"Becker","year":"1994","journal-title":"Cancer Res"},{"issue":"23","key":"10.1016\/j.urolonc.2019.03.001_bib0026","doi-asserted-by":"crossref","first-page":"3756","DOI":"10.1007\/s00018-008-8281-1","article-title":"The cell-cell adhesion molecule E-cadherin","volume":"65","author":"van Roy","year":"2008","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.urolonc.2019.03.001_bib0027","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.2741\/4031","article-title":"Soluble E-cadherin: more than a symptom of disease","volume":"17","author":"Grabowska","year":"2012","journal-title":"Front Biosci"},{"issue":"4","key":"10.1016\/j.urolonc.2019.03.001_bib0028","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.clgc.2018.01.008","article-title":"Role of WNT\/beta-Catenin Pathway as Potential Prognostic and Predictive Factors in Renal Cell Cancer Patients Treated With Everolimus in the Second and Subsequent Lines","volume":"16","author":"Bodnar","year":"2018","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.urolonc.2019.03.001_bib0029","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s13046-015-0161-6","article-title":"sE-cadherin serves as a diagnostic and predictive parameter in prostate cancer patients","volume":"34","author":"Tsaur","year":"2015","journal-title":"J Exp Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.urolonc.2019.03.001_bib0030","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1016\/j.jss.2011.11.009","article-title":"Clinical significance of serum soluble E-cadherin in colorectal carcinoma","volume":"175","author":"Okugawa","year":"2012","journal-title":"J Surg Res"},{"issue":"6","key":"10.1016\/j.urolonc.2019.03.001_bib0031","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1002\/ijc.25438","article-title":"Soluble E-cadherin as a serum biomarker candidate: elevated levels in patients with late-stage colorectal carcinoma and FAP","volume":"128","author":"Weiss","year":"2011","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.urolonc.2019.03.001_bib0032","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.eururo.2005.02.012","article-title":"Urinary levels of soluble e-cadherin in the detection of transitional cell carcinoma of the urinary bladder","volume":"48","author":"Shariat","year":"2005","journal-title":"Eur Urol"},{"issue":"6 Pt 1","key":"10.1016\/j.urolonc.2019.03.001_bib0033","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1097\/01.ju.0000094189.93805.17","article-title":"Preoperative plasma soluble E-cadherin predicts metastases to lymph nodes and prognosis in patients undergoing radical cystectomy","volume":"170","author":"Matsumoto","year":"2003","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/j.urolonc.2019.03.001_bib0034","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1136\/gut.48.6.808","article-title":"Soluble E-cadherin is a valid prognostic marker in gastric carcinoma","volume":"48","author":"Chan","year":"2001","journal-title":"Gut"},{"issue":"85","key":"10.1016\/j.urolonc.2019.03.001_bib0035","first-page":"1390","article-title":"Significance of the serum level of soluble E-cadherin in patients with HCC","volume":"55","author":"Soyama","year":"2008","journal-title":"Hepatogastroenterology"},{"issue":"5","key":"10.1016\/j.urolonc.2019.03.001_bib0036","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1378\/chest.10-0157","article-title":"Soluble adhesion molecules E-cadherin, intercellular adhesion molecule-1, and E-selectin as lung cancer biomarkers","volume":"138","author":"Gogali","year":"2010","journal-title":"Chest"},{"issue":"8","key":"10.1016\/j.urolonc.2019.03.001_bib0037","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1038\/bjc.1998.634","article-title":"Characterization of soluble E-cadherin as a disease marker in gastric cancer patients","volume":"78","author":"Gofuku","year":"1998","journal-title":"Br J Cancer"},{"issue":"10","key":"10.1016\/j.urolonc.2019.03.001_bib0038","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1089\/end.2011.0673","article-title":"Transient variations in the serum concentrations of cell adhesion molecules following retroperitoneal laparoscopic and open radical nephrectomy for localized renal-cell carcinoma","volume":"26","author":"Yang","year":"2012","journal-title":"J Endourol"},{"issue":"23","key":"10.1016\/j.urolonc.2019.03.001_bib0039","first-page":"4366","article-title":"Carcinoma cells induce lumen filling and EMT in epithelial cells through soluble E-cadherin-mediated activation of EGFR","volume":"128","author":"Patil","year":"2015","journal-title":"J Cell Sci"},{"issue":"26","key":"10.1016\/j.urolonc.2019.03.001_bib0040","doi-asserted-by":"crossref","first-page":"18393","DOI":"10.1074\/jbc.M801329200","article-title":"The ectodomain shedding of E-cadherin by ADAM15 supports ErbB receptor activation","volume":"283","author":"Najy","year":"2008","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/j.urolonc.2019.03.001_bib0041","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/onc.2012.563","article-title":"Soluble E-cadherin: a critical oncogene modulating receptor tyrosine kinases, MAPK and PI3K\/Akt\/mTOR signaling","volume":"33","author":"Brouxhon","year":"2014","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.urolonc.2019.03.001_bib0042","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/toxsci\/51.1.80","article-title":"Chemically induced oxidative stress disrupts the E-cadherin\/catenin cell adhesion complex","volume":"51","author":"Parrish","year":"1999","journal-title":"Toxicol Sci"},{"issue":"11","key":"10.1016\/j.urolonc.2019.03.001_bib0043","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1007\/s00464-001-9221-4","article-title":"Serum E-cadherin concentrations and their response during laparoscopic and open cholecystectomy","volume":"16","author":"Karayiannakis","year":"2002","journal-title":"Surg Endosc"},{"issue":"5","key":"10.1016\/j.urolonc.2019.03.001_bib0044","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1080\/1354750X.2018.1434682","article-title":"Plasma sE-cadherin and the plasma sE-cadherin\/sVE-cadherin ratio are potential biomarkers for chronic obstructive pulmonary disease","volume":"23","author":"Shirahata","year":"2018","journal-title":"Biomarkers"},{"issue":"16-17","key":"10.1016\/j.urolonc.2019.03.001_bib0045","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1016\/j.clinbiochem.2016.07.011","article-title":"Soluble E-cadherin as a serum biomarker in patients with HBV-related liver diseases","volume":"49","author":"Wang","year":"2016","journal-title":"Clin Biochem"},{"issue":"10","key":"10.1016\/j.urolonc.2019.03.001_bib0046","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.3899\/jrheum.130518","article-title":"Soluble E-cadherin in systemic lupus erythematosus","volume":"40","author":"Jin","year":"2013","journal-title":"J Rheumatol"},{"key":"10.1016\/j.urolonc.2019.03.001_bib0047","doi-asserted-by":"crossref","DOI":"10.1155\/2009\/397375","article-title":"Soluble E-cadherin: an early marker of severity in acute pancreatitis","volume":"2009","author":"Sewpaul","year":"2009","journal-title":"HPB Surg"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143919300948?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143919300948?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:16:08Z","timestamp":1761041768000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143919300948"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":46,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S1078143919300948"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2019.03.001","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"sE-cadherin is upregulated in serum of patients with renal cell carcinoma and promotes tumor cell dissemination in vitro","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2019.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}